Hearing Loss Trial, Recruiting NCT07548944 Sponsor: Okuvision GmbH Condition: Hearing Loss
Back to Hearing Loss

Hearing Loss Trial, Recruiting

NCT07548944
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been clinically diagnosed with retinitis pigmentosa or a similar condition where the retina gradually deteriorates over time
  • People who are currently using a device called the OkuStim® System for transcorneal electrical stimulation (a treatment that applies mild electrical signals to the eye) as it is intended to be used
  • People who have noticed short-term effects on their vision or symptoms after receiving this electrical stimulation treatment
  • People who are willing and able to give their informed consent to participate in the study

Who may not be able to join:

  • People who have cognitive, psychological, or language difficulties that would make it hard to give informed consent or take part properly in the study
  • People who have other eye conditions — such as cataracts, glaucoma, or macular degeneration — that the trial doctor believes could interfere with or confuse the study results
  • People who are currently taking part in another clinical trial that could affect this study's results
  • People who have serious other health conditions that could put their safety at risk or make it difficult to carry out the study properly

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dr. med. Svenja Deuchler, Augenzentrum Frankfurt Prof. Koch GmbH

Phone: +49 69 7566 8880

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Okuvision GmbH
Registry
ClinicalTrials.gov
Start date
20 April 2026
Est. completion
1 March 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Best-corrected visual acuity; Contrast sensitivity; Retinal sensitivity; Subjective changes in visual performance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov